Kiniksa is a development-stage biopharmaceutical company focused on acquiring, discovering, developing and delivering therapeutics for patients suffering from debilitating diseases and unmet medical needs. Kiniksa was formed in 2015 by several members of our senior management team who had previously worked together with the goal of creating a leading biopharmaceutical company focused on helping patients with unaddressed needs. We have built a pipeline of product candidates that includes potential therapies across all stages of development for the treatment of autoinflammatory and autoimmune conditions. The patients we seek to serve have substantial unmet needs due to either the severity of their disease or the shortcomings of the products that are currently available to them. Each of our programs has the potential to be best-in-class, first-in-class, or the first available commercially-approved treatment for the diseases we are targeting.
